3 Things In Biotech You Should Learn Today: October 2, 2017


Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. In 2017, one of the more powerful undercurrents has been the development of treatment options for early-stage HER2-positive breast cancer, specifically after surgery .



from Biotech News